A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs

A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs

Background and objective Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with negative drive gene and positive programmed cell...

Full description

Bibliographic Details
Main Authors: Ran CHEN, Xiang GAO, Fudong XU, Shucai ZHANG, Li MA, Bo HU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-03-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
epidermal growth factor receptor mutation
programmed cell death ligand 1 expression
targeted treatment
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.09

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.09

Similar Items